Modelling precise responses to anti-seizure medication using brain organoids carrying SCN2A-GoF and SCN2A-LoF mutations

This study uses brain organoid models to investigate how gain-of-function and loss-of-function SCN2A mutations affect response to anti-seizure medications, potentially enabling personalized treatment approaches for epilepsy patients. The research applies modern neurodevelopmental modeling techniques to understand drug responsiveness at the cellular level.